Exelixis
EXEL
#1343
Rank
A$24.10 B
Marketcap
A$98.78
Share price
-3.60%
Change (1 day)
52.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): A$5.04

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$5.19. In 2025 the company made an earnings per share (EPS) of A$4.34.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$5.0416.23%
2025A$4.34
2023A$0.9814.61%
2022A$0.86-22.97%
2021A$1.11100%
2020A$0.56-65.09%
2019A$1.59-53.91%
2018A$3.45333.96%
2017A$0.80-260.61%
2016A-$0.50-58.75%
2015A-$1.20-42.45%
2014A-$2.095.3%
2013A-$1.98

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$10.02 93.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.07-79.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$26.08 402.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.97-42.76%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$1.49-71.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$6.78 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$4.32-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$21.34-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.26-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA